Top Markets
#1 Pleasing Gold Pleasing Gold +1,501.46%
#2 Ontology Gas Ontology Gas +131.75%
#3 PulseChain PulseChain +61.85%
#4 Osmosis Osmosis +35.55%
#5 BOOK OF MEME BOOK OF MEME +31.03%
#6 Ontology Ontology +30.60%
#7 Neiro Neiro +30.07%
#8 Collect on Fanable Collect on Fanable +28.80%
#9 Unit Pump Unit Pump +28.63%
#10 Pump.fun Pump.fun +28.63%
Coin of the day
Pleasing Gold Pleasing Gold
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
LAVA Therapeutics N.V. LAVA Therapeutics N.V.

LAVA Therapeutics N.V.

LVTX
Classifica tra le azioni #25846
LAVA Therapeutics N.V. is an immuno-oncology firm, currently in the clinical... LAVA Therapeutics N.V. is an immuno-oncology firm, currently in the clinical development phase, dedicated to pioneering novel therapies for cancer. Utilizing its proprietary Gammabody platform, the company engineers innovative bispecific antibodies. These antibodies are specifically designed to engage and harness the potent and precise capabilities of gamma delta T cells, aiming to stimulate a robust anti-tumor immune response and ultimately enhance outcomes for individuals battling cancer. Key compounds in its clinical pipeline include LAVA-051, currently undergoing Phase 1/2a trials for various hematologic malignancies such as chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. Another front-runner, LAVA-1207, is also in Phase 1/2a clinical studies, targeting metastatic castration-resistant prostate cancer. Furthermore, LAVA Therapeutics is advancing additional Gammabody candidates: LAVA-1223, an investigational treatment for specific solid tumors that targets the epidermal growth factor receptor (EGFR), and preclinical assets LAVA-1266 and LAVA-1278, intended for a range of blood cancers. The company has also forged a research collaboration and licensing partnership with Janssen Biotech, Inc. This alliance focuses on the potential discovery and development of multi-specific antibody therapies aimed at a particular target across diverse therapeutic applications. Established in 2016, LAVA Therapeutics N.V. operates from its headquarters in Utrecht, the Netherlands.
Prezzo delle azioni
$1.74
Ultima sincronizzazione: 2025-11-28
Capitalizzazione di mercato
$45.77M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
13.73%
Paese
NL
Scambia LAVA Therapeutics N.V. (LVTX)

Categoria

Healthcare
Utile per LAVA Therapeutics N.V. (LVTX)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di LAVA Therapeutics N.V., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di LAVA Therapeutics N.V. dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US